Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Trial of SYN125 Single Agent in Solid Tumors and in Combination With Fixed Dose SYN004 in Patients With Epithelial Cancers With EGFR Expressions.

NCT04363242 is registered in ClinicalTrials.gov with Synermore Biologics Co., Ltd. as lead sponsor.

NCT NCT04363242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04363242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Trial of SYN125 Single Agent in Solid Tumors and in Combination With Fixed Dose SYN004 in Patients With Epithelial Cancers With EGFR Expressions.
Lead sponsor
Synermore Biologics Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
April 9, 2020
Completion date
September 30, 2023
Enrollment
22 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial carcinoma, solid tumor